Frank, Samuel
Anderson, Karen E.
Fernandez, Hubert H.
Hauser, Robert A.
Claassen, Daniel O.
Stamler, David
Factor, Stewart A.
Jimenez-Shahed, Joohi
Barkay, Hadas
Wilhelm, Amanda
Alexander, Jessica K.
Chaijale, Nayla
Barash, Steve
Savola, Juha-Matti
Gordon, Mark Forrest
Chen, Maria
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
https://doi.org/10.1007/s40120-024-00600-1
Documents that mention this clinical trial
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
https://doi.org/10.1007/s40120-024-00600-1
Documents that mention this clinical trial
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
https://doi.org/10.1007/s40120-024-00600-1
Documents that mention this clinical trial
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
https://doi.org/10.1136/jnnp-2018-319918
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
https://doi.org/10.1007/s40120-024-00600-1
Documents that mention this clinical trial
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
https://doi.org/10.1007/s40263-022-00956-8
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
https://doi.org/10.1007/s40120-024-00600-1
Funding for this research was provided by:
Teva Branded Pharmaceutical Products R&D, Inc.
Article History
Received: 19 October 2023
Accepted: 4 March 2024
First Online: 1 April 2024
Declarations
:
: Samuel Frank is principal investigator of First-HD and ARC-HD (Teva), consultant for Novartis, Sage Therapeutics, and uniQure, and has received research support from Cure Huntington’s Disease Initiative Foundation, Huntington’s Disease Society of America, the Huntington Study Group, Neurocrine, Roche/Genentech, and Triplet Therapeutics. Karen E. Anderson is global principal/co-principal investigator of AIM-TD and ARM-TD (Teva Pharmaceuticals; funds paid directly to her institution, Georgetown University), North American study co-principal investigator of LEGATO-HD (Teva), site principal investigator of Pride-HD, First-HD, and ARC-HD (Teva), ENROLL-HD (Cure Huntington’s Disease Initiative Foundation), Vaccinex, and site investigator for Generation HD studies (Roche Biogen). She is a consultant for NeuroNEXT 105 study (Azevan) and scientific advisor for Azevan, Biogen, Cure Huntington’s Disease Initiative Foundation, Novartis, Prana, and Roche. She has received salary support from The Griffin Foundation and Honoraria from Vindico Medical Education. Hubert H. Fernandez has received honoraria from AbbVie, Biogen, Carling Communications, GE Health Care, inVentiv, International Parkinson and Movement Disorders Society, Kyowa Hakko Kirin, Lundbeck, Medscape (speaker in CME events), Merz Pharmaceuticals, Pfizer (as a consultant), Prime Education, Sunovion, and Voyager Therapeutics. He has been provided grant and research support by AbbVie, Acadia, Biotie/Acorda, Civitas, Kyowa/ProStrakan, Michael J. Fox Foundation, Movement Disorders Society, National Institute of Health/National Institute of Neurological Disorders and Stroke, Parkinson Study Group, Rhythm Pharmaceuticals, Synosia, Teva Pharmaceuticals. He has received royalties from Demos Publishing (serving as a book author/editor) and contractual services with The Cleveland Clinic via a contract with Teva for Dr Fernandez’s role as co-principal investigator in SD-809 tardive dyskinesia global studies. Dr Fernandez also serves as a member of the publication committee for Acorda, but does not receive any personal compensation for this. He has received a stipend from the International Parkinson and Movement Disorders Society for serving as medical editor for the MDS website. Robert A. Hauser has served as a consultant with AbbVie, Academy for Continued Healthcare Learning, Acorda, Adamas Pharmaceuticals, AstraZeneca, Back Bay Life Science, Biotie, ClearView Healthcare Partners, ClinicalMind Medical and Therapeutic Communications, Cowen and Company, Cynapsus, eResearch Technology, Expert Connect, Gerson Lehrman Group, Guidepoint Global, Health Advances, HealthLogiX, Impax Laboratories, Kyowa Kirin Pharmaceutical Development, LCN Consulting, LifeMax, Lilly, Lundbeck, Michael J. Fox Foundation, National Institutes of Health, National Parkinson Foundation, Neurocrine, Neuropore, Outcomes Insights, PeerView Press, Pfizer, Pharma Two B Ltd., Prexton, Projects in Knowledge, Putnam Associates, Quintiles, RMEI Medical Education for Better Outcomes, Sarepta, Sunovion, Teva Pharmaceuticals, US WorldMeds, and Vista Research. Daniel O. Claassen has received research support from Griffin Foundation, Huntington’s Disease Society of America, Michael J. Fox Foundation, National Institute of Neurological Disorders and Stroke, and National Institute on Aging, and grant support from AbbVie, Acadia, Biogen, Bristol Myers Squibb, Cerecor, Jazz Pharmaceuticals, Lilly, Lundbeck, Teva Pharmaceuticals, Vaccinex, and Wave Life Sciences. Dr Claassen is a consultant/scientific advisor for Acadia, Adamas Pharmaceuticals, Alterity, Lundbeck, Neurocrine, Teva Pharmaceuticals, and Wave Life Sciences. David Stamler is a former employee of Teva Pharmaceuticals. He receives salary and benefits from Auspex Pharmaceuticals. Patents pending: US20160346270, US20160287574. Stewart A. Factor has received honoraria from Acorda, Biogen, CereSpir, Neurocrine, Lundbeck, Teva Pharmaceuticals, Avanir, UCB, US WorldMeds, Sunovion, and Adamas Pharmaceuticals. He has received research support from Biohaven, Boston Scientific, Impax, Ipsen, Jazz Pharmaceuticals, Lilly, Medtronic, National Institutes of Health (U10 NS077366), Neurocrine, Parkinson Foundation, Sun Pharmaceuticals Advanced Research Company, Voyager Therapeutics, Auspex, US WorldMeds, Pharm-Olam, Cynapsus/Sunovion, Vaccinex, Solstice, Cure Huntington’s Disease Initiative Foundation, Michael J. Fox Foundation. He has received royalties from Demos, Blackwell Futura, Springer (textbooks), Uptodate. He has other conflicts of interest with Signant Health (Bracket Global LLC) and CNS Ratings. Joohi Jimenez-Shahed has received consulting fees from AbbVie, Blue Rock Therapeutics, Bracket Global, Medtronic, Nuvelution, Photopharmics, St. Jude Medical, Teva Pharmaceuticals. Hadas Barkay is an employee of Teva Pharmaceutical Industries Ltd. Amanda Wilhelm and Jessica K. Alexander are former employees of Teva Branded Pharmaceutical Products R&D, Inc. Nayla Chaijale, Steve Barash, Mark Forrest Gordon, and Maria Chen are employees of Teva Branded Pharmaceutical Products R&D, Inc. Juha-Matti Savola is a former employee of Teva Pharmaceuticals International GmbH, Basel, Switzerland.
: This article is based on previously conducted studies and did not require any approvals or informed consent; approval and consent were obtained with conduct of the initial studies, which were in accordance with the Declaration of Helsinki.